You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NSCLC, EGFR mutation

Showing 1 - 25 of 6,944
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Shanghai (IN10018, Furmonertinib)

Recruiting
  • NSCLC
  • Shanghai, China
    Shanghai Pulmonary Hospital
Aug 8, 2023

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

Not yet recruiting
  • Aumolertinib
  • +4 more
  • (no location specified)
Mar 8, 2023

Non-Small-Cell Lung Cancer Trial in Guangzhou (PLB1004)

Recruiting
  • Non-Small-Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong General Hospital
Aug 25, 2023

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

Central Nervous System Metastatic EGFR Mutation Positive NSCLC

Not yet recruiting
  • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 6, 2023

    Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC

    Completed
    • Non-small Cell Lung Cancer
    • (no location specified)
    May 8, 2023

    NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)

    Not yet recruiting
    • NSCLC
    • +2 more
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
    Jul 9, 2023

    NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

    Recruiting
    • NSCLC
    • EGFR Gene Mutation
    • neo-antigen vaccine
    • Nanjing, China
      The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
    Oct 19, 2023

    NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
    • (no location specified)
    Aug 27, 2023

    NSCLC Trial (Idylla EGFR_IUO/3.20 Mutation Test)

    Not yet recruiting
    • NSCLC
    • Idylla EGFR_IUO/3.20 Mutation Test
    • (no location specified)
    Jul 24, 2023

    A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

    Recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • +4 more
      • Guangzhou, Guangdong, China
        Cancer Center, Sun Yat-sen University
      Oct 25, 2022

      Brain Metastases, Radiotherapy, EGFR Activating Mutation Trial in Guangdong (brain radiotherapy, Almonertinib)

      Recruiting
      • Brain Metastases
      • +2 more
      • Guangdong, Guangzhou, China
        Sun-Yat-Sen university
      Mar 13, 2023

      EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

      Recruiting
      • EGFR Exon 20 Mutation
      • +3 more
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 12, 2022

      EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy

      Not yet recruiting
      • EGF-R Positive Non-Small Cell Lung Cancer
      • +4 more
      • Stereotactic Body Radiation Therapy SBRT
      • Bogotá, Colombia
        CTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C
      Aug 16, 2023

      NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • (no location specified)
      May 23, 2023

      NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Kunming (Combined therapy of anlotinib and aumolertinib)

      Recruiting
      • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
      • Combined therapy of anlotinib and aumolertinib
      • Kunming, Yunnan, China
        First Affiliated Hospital of Kunming University
      Oct 22, 2023

      NSCLC Trial in China (HSK40118)

      Recruiting
      • NSCLC
      • Beijing, Beijing, China
      • +11 more
      Sep 18, 2023

      Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor Trial in Jerusalem (concomitant TTFields treatment

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • +2 more
      • concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
      • concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
      • Jerusalem, Israel
        Shaare Zedek Medical Center
      Jan 22, 2023

      NSCLC Trial in Shanghai (Furmonertinib 160mg, Furmonertinib 240mg)

      Recruiting
      • NSCLC
      • Furmonertinib 160mg
      • Furmonertinib 240mg
      • Shanghai, China
        Shanghai Chest hospital
      Jan 16, 2023

      Non-squamous NSCLC Trial (biological, drug, dietary supplement)

      Not yet recruiting
      • Non-squamous NSCLC
      • Pembrolizumab
      • +7 more
      • (no location specified)
      Feb 20, 2023

      Furmonertinib, EGFR-mutation, NSCLC Trial in Beijing (Furmonertinib)

      Recruiting
      • Furmonertinib
      • +3 more
      • Beijing, China
        Ethics Committee
      Jul 15, 2022

      Learn About Tests Looking forGene Mutation in Lung Cancer in

      Not yet recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • No Intervention
      • Beijing, China
        Department of Pathology, National Cancer Center/National Clinica
      Feb 24, 2023

      NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

      Terminated
      • Carcinoma, Non-Small-Cell Lung
      • Maastricht, Limburg, Netherlands
      • +4 more
      Nov 7, 2022

      NSCLC Trial (QLH11811)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • (no location specified)
      Sep 22, 2022